Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03838770 · ClinicalTrials.gov registry record · NA

tDCS for the Management of Multiple Sclerosis Related Fatigue

A NA study of Multiple Sclerosis, sponsored by NYU Langone Health.

Completed
Registry status
NA
Development phase
122
Enrollment target
1
Study location

NCT03838770 is a NA study of Multiple Sclerosis that has completed, run by NYU Langone Health. The registered enrollment target is 122 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03838770, a NA study of Multiple Sclerosis, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
NA
Development phase
122 participants
Enrollment target
1
Study location

Study Summary

This is a pragmatic clinical trial that aims to determine the effect of tDCS on symptomatic fatigue in Multiple Sclerosis (MS) patients. This is a randomized, blinded, sham-controlled study design to determine the effect of Transcranial Direct Current Stimulation (tDCS) on MS participants to reduce feelings of fatigue.120 participants with MS and clinically-significant fatigue (as defined by a score of \>36 on the Fatigue Severity Scale) will be recruited to participate in either an active or sham treatment condition.

Conditions Studied

Interventions

  • DEVICE sham tDCS
  • DEVICE Active tDCS

Study Locations (1)

New York

  • NYU Langone Health - New York

Trial Details

FieldValue
Enrollment Target 122 participants
Start Date 2019-04-04
Est. Completion 2021-06-30
Phase NA

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT03838770

The ClinicalTrials.gov registry entry for NCT03838770 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (79% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which sham tDCS is the first listed.

NCT03838770 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03838770 about?

NCT03838770 is a clinical study titled "tDCS for the Management of Multiple Sclerosis Related Fatigue". This is a pragmatic clinical trial that aims to determine the effect of tDCS on symptomatic fatigue in Multiple Sclerosis (MS) patients. This is a randomized, blinded, sham-controlled study design to determine the effect of Transcranial Direct Current Stimulation (tDCS) on MS participants to reduce ...

What is the current status of trial NCT03838770?

This trial is currently completed. It is a NA study. The enrollment target is 122 participants. The study started on 2019-04-04. Estimated completion is 2021-06-30.

What conditions does trial NCT03838770 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT03838770?

The interventions under investigation include: sham tDCS (DEVICE), Active tDCS (DEVICE).

Who is sponsoring clinical trial NCT03838770?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03838770 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.